Singapore Medical Group (SMG)

SINGAPORE (Oct 17): People say money cannot buy self-esteem, but it sure can buy a whole new look. The aesthetic and wellness industry is booming, with the affluent market demanding to look their best, whether that means getting a new chin or looking year

SINGAPORE (Aug 7): Singapore Medical Group saw its earnings rise 3.5% to $3.5 million for the 2Q19 ended June, from $3.4 million a year ago.

SINGAPORE (June 7): RHB Research is upgrading Singapore Medical Group (SMG) to “buy” from “neutral” previously, with an unchanged target price of 48 cents.

SINGAPORE (Feb 21): RHB Research is maintaining Singapore Medical Group (SMG) at “buy” on news that shareholder CHA Healthcare Singapore (CHAS) is raising its stake in the group.

SINGAPORE (Feb 20): Singapore Medical Group (SMG) at noon on Wednesday called for a trading halt “pending [the] release of [an] announcement”.

SINGAPORE (Feb 19): Singapore Medical Group (SMG) posted a 17.2% rise in 4Q18 earnings to $2.9 million from $2.5 million a year ago, driven by increased revenue contributions from the health and diagnostic & aesthetic business segments.

SINGAPORE (Jan 2): RHB Research prefers to stay selective and defensive amid growth uncertainties in 2019.

SINGAPORE (May 16): RHB Research says Singapore Medical Group must be doing something right to capture market share in the private medical practice space from its competitors.

SINGAPORE (May 15): Singapore Medical Group, the healthcare services provider with an expanding regional network, reported 1Q18 earnings more than doubled to $3.4 million from $1.4 million.